Back to Journals » ClinicoEconomics and Outcomes Research » Volume 8

Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting

Authors Perrone V, Sangiorgi D, Buda S, Degli Esposti L

Received 11 March 2016

Accepted for publication 1 July 2016

Published 14 October 2016 Volume 2016:8 Pages 591—597

DOI https://doi.org/10.2147/CEOR.S108288

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Professor Giorgio Lorenzo Colombo

Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti

CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy

Introduction: Hepatitis C virus (HCV) infection represents serious health problems worldwide and is a major contributor to end-stage liver disease including cirrhosis and hepatocellular carcinoma (HCC). In Italy, ~2% of subjects are infected with HCV. The objective of this study was to describe treatment patterns, disease progression, and resource use in HCV.
Methods: An observational retrospective cohort analysis based on four Local Health Units administrative and laboratory databases was conducted. HCV-positive patients between January 1, 2009 and December 31, 2010 were included and followed-up for 1 year. To explore which covariates were associated to disease progression (cirrhosis, HCC, death for any cause), Cox proportional hazards models were performed.
Results: A total of 9,514 patients were analyzed of which 55.6% were male, aged 58.1±16.1, and prevalence 0.4%; 5.8% were positive to human immunodeficiency virus (HIV) infection, 3.0% to hepatitis B virus (HBV), and 1.6% to HCV+HBV+HIV; 26.1% had cirrhosis and 4.3% HCC. The majority of patients (76%) did not receive an antiviral treatment; the main factors affecting this decision were age, 44.1% of untreated patients being aged >65 years; 31% were affected by cirrhosis, 6.6% had ongoing substance or alcohol abuse, and 5.5% were affected by HCC. Disease progression in the observed timeframe was less frequent among treated patients (incidence rate per 100 patients/year: cirrhosis 2.1±0.7 vs 13.0±1.0, HCC 0.5±0.3 vs 3.6±0.5, death 0.5±0.3 vs 6.4±0.7). The annual expenditure for HCV management (drugs, hospitalizations, outpatient services) was €4,700 per patient.
Conclusion: This observational, real-life study shows that only a small proportion of patients received antiviral therapy in the territorial services investigated; among patients who were not treated, this is reflected in a disease progression and cost of management higher than treated patients. These results suggest the importance of better defining the categories of patients who can really postpone treatment, and those who require immediate antiviral therapy.

Keywords: hepatitis C virus, HCV, hepatocellular carcinoma, HCC, cirrhosis, real practice, cost of illness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2017, 9:609-616

Published Date: 10 October 2017

Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study

Ermini G, Perrone V, Veronesi C, Degli Esposti L, Di Pasquale G

Vascular Health and Risk Management 2017, 13:239-246

Published Date: 5 July 2017

Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy

Degli Esposti L, Veronesi C, Perrone V, Buda S, Santoro A

ClinicoEconomics and Outcomes Research 2017, 9:233-239

Published Date: 27 April 2017

Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study

Perrone V, Sangiorgi D, Buda S, Degli Esposti L

ClinicoEconomics and Outcomes Research 2016, 8:649-655

Published Date: 25 October 2016

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L

Biologics: Targets and Therapy 2015, 9:119-127

Published Date: 6 November 2015

Adherence to statin treatment following a myocardial infarction: an Italian population-based survey

Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, Grion A, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2015, 7:273-280

Published Date: 1 June 2015

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study

Degli Esposti L, Sangiorgi D, Perrone V, Radice S, Clementi E, Perone F, Buda S

ClinicoEconomics and Outcomes Research 2014, 6:401-407

Published Date: 18 September 2014

Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting

Degli Esposti L, Saragoni S, Buda S, Degli Esposti E

ClinicoEconomics and Outcomes Research 2014, 6:209-216

Published Date: 22 April 2014

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E

ClinicoEconomics and Outcomes Research 2013, 5:193-201

Published Date: 14 May 2013

Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients

Luca Degli Esposti, Stefania Saragoni, Silvia Benemei, et al

ClinicoEconomics and Outcomes Research 2011, 3:47-54

Published Date: 7 March 2011

Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years

Luca Degli Esposti, Stefania Saragoni, Paolo Batacchi, et al

ClinicoEconomics and Outcomes Research 2010, 2:113-120

Published Date: 28 July 2010